INmune Bio, Inc.
INMB
Price:
$4.88
Market Cap:
$108.20M
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsb...[Read more]
Industry
Biotechnology
IPO Date
2019-02-04
Stock Exchange
NASDAQ
Ticker
INMB
PE Ratio
[-2.24]
ROE
[-115.51%]
Current Ratio
[2.59]
Dividend Yield
[0%]
Enterprise Value
[77.56M]
Dividend History
The ROE as of November 2024 (TTM) for INmune Bio, Inc. (INMB) is -115.51%
According to INmune Bio, Inc.’s latest financial reports and current stock price. The company's current ROE is -115.51%. This represents a change of 292.95% compared to the average of -29.40% of the last 4 quarters.
INmune Bio, Inc. (INMB) Historical ROE (quarterly & annually)
How has INMB ROE performed in the past?
The mean historical ROE of INmune Bio, Inc. over the last ten years is 14.56%. The current -115.51% ROE has changed -893.19% with respect to the historical average. Over the past ten years (40 quarters), INMB's ROE was at its highest in in the December 2016 quarter at 90.26%. The ROE was at its lowest in in the March 2024 quarter at -37.99%.
Average
14.56%
Median
-37.82%
Minimum
-78.68%
Maximum
259.00%
INmune Bio, Inc. (INMB) ROE by Quarter and Year
Discovering the peaks and valleys of INmune Bio, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.54%
Maximum Annual ROE = 259.00%
Minimum Annual Increase = -102.47%
Minimum Annual ROE = -78.68%
| Year | ROE | Change |
|---|---|---|
| 2023 | -78.68% | 65.08% |
| 2022 | -47.66% | 26.03% |
| 2021 | -37.82% | 21.13% |
| 2020 | -31.22% | -19.38% |
| 2019 | -38.72% | -48.51% |
| 2018 | -75.21% | 1.54% |
| 2017 | -4.59% | -102.47% |
| 2016 | 185.98% | -28.19% |
INmune Bio, Inc. (INMB) Average ROE
How has INMB ROE performed in the past?
The current ROE of INmune Bio, Inc. (INMB) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-54.72%
5-year avg
-46.82%
10-year avg
14.56%
INmune Bio, Inc. (INMB) ROE vs. Peers
How is INMB’s ROE compared to its peers?
INmune Bio, Inc.’s ROE is greater than TFF Pharmaceuticals, Inc. (-310.17%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), greater than Abcam plc (-1.23%), greater than AN2 Therapeutics, Inc. (-57.63%), greater than Cue Biopharma, Inc. (-156.38%), greater than Anixa Biosciences, Inc. (-52.41%), greater than IN8bio, Inc. (-197.15%), greater than PolyPid Ltd. (-1219.71%), greater than Aerovate Therapeutics, Inc. (-90.19%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than Decibel Therapeutics, Inc. (-56.38%), greater than Anavex Life Sciences Corp. (-30.63%), greater than Cassava Sciences, Inc. (-12.36%), greater than BioVie Inc. (-188.95%), greater than Cognition Therapeutics, Inc. (-150.93%), greater than TScan Therapeutics, Inc. (-58.72%), greater than Dermata Therapeutics, Inc. (-247.40%),
| Company | ROE | Market cap |
|---|---|---|
| -310.17% | $1.35M | |
| -184.40% | $36.31M | |
| -1.23% | $5.52B | |
| -57.63% | $41.48M | |
| -156.38% | $69.05M | |
| -52.41% | $106.84M | |
| -197.15% | $22.47M | |
| -1219.71% | $23.85M | |
| -90.19% | $77.38M | |
| -47.03% | $342.68M | |
| -56.38% | $123.37M | |
| -30.63% | $766.13M | |
| -12.36% | $184.02M | |
| -188.95% | $50.11M | |
| -150.93% | $16.81M | |
| -58.72% | $247.64M | |
| -247.40% | $2.25M |
Build a custom stock screener for INmune Bio, Inc. (INMB) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like INmune Bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
INmune Bio, Inc. (INMB) and other stocks custom spreadsheet templates
The easiest way to analyze a company like INmune Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is INmune Bio, Inc.'s ROE?
How is the ROE calculated for INmune Bio, Inc. (INMB)?
What is the highest ROE for INmune Bio, Inc. (INMB)?
What is the 3-year average ROE for INmune Bio, Inc. (INMB)?
What is the 5-year average ROE for INmune Bio, Inc. (INMB)?
How does the current ROE for INmune Bio, Inc. (INMB) compare to its historical average?